Latest News
Coronavirus (COVID-19) and MS
We know many people living with MS in Australia (and worldwide) are anxious about coronavirus – a new respiratory illness – and what it means for them.
Deidre Mackechnie, CEO, MS Australia says,
“we are aware of the concerns of the MS community in Australia. MS...
Parliamentary Friends of Multiple Sclerosis - Briefing on the latest MS research developments
MS Australia welcomes Adam Bandt as the new Greens Leader
MS Australia welcomes the election of Adam Bandt as the new Leader of the Australian Greens in the Australian Parliament.
MS Australia has always enjoyed a progressive and productive relationship with the Australian Greens, including representation on our...
MS treatments on PBAC’s March 2020 agenda
It’s unusual to have three medications for treating MS before a meeting of the Pharmaceutical Benefits Advisory Committee (PBAC), for consideration for listing on the Pharmaceutical Benefits...
NDIS Tune Review sets the scene for (long overdue) change
MS Australia joins other disability peak organisations in welcoming the Tune Review...
Paralympian cyclist Emily Petricola talks to MS Australia about life with MS and training for Tokyo 2020.
Smart, funny and incredibly fit, Emily Petricola calls herself the “Queen of Denial”. “I prefer not to think about the things that are affecting my body”, says Emily.
Nevertheless, she is keen to work with MS Australia to broaden awareness of MS around the nation. Emily feels...
Are you in a current bushfire area?
If you are experiencing wheezing, chest tightness and difficulty breathing you should call triple zero (000) or TTY Emergency Service: Dial 106.
Please ensure you stay informed:
State specific information
ACT:
...
PBS listing for Siponimod (brand name Mayzent®) for SPMS not recommended by PBAC
The Pharmaceutical Benefits Advisory Committee (PBAC) announced today (20/12/19), that they have not recommended the listing of siponimod (Mayzent®) for secondary progressive MS (SPMS) on the Pharmaceutical Benefits Scheme (PBS), stating as follows:
“The PBAC did not recommend the listing...
Application to list Sativex on the PBS
MS Australia has been informed by Emerge Health that they have made an application to the March 2020 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) to have the medicinal cannabis product Sativex listed on the Pharmaceutical Benefits Scheme (PBS) for spasticity in MS. If...
MS Australia pays tribute to the life of Dr Leslie (Ladislav) Sedal, M.B, B.S., FRACP, M Ed. (04/09/1944 - 16/11/2019)
MS Australia’s top award presented to Professor Michael Pender
MS Australia is thrilled to announce that Professor Michael...
Australian Government approves amended PBS listing of two MS medications for children with RRMS, from 1 November 2019.
Today (Monday 28 October 2019) the Federal Health Minister, the Hon Greg Hunt MP announced the (amended) listing of two MS medications for children with relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS), from 1 November 2019.
The Federal Health Minister’s media...